2. Search Result
Search Result
Pathways Recommended: Cell Cycle/DNA Damage
Results for "

DNA DSB

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

3

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1357
    Digitoxin
    5+ Cited Publications

    		 Environmental Pollutants Apoptosis Na+/K+ ATPase Bcl-2 Family Caspase HSV Calcium Channel Cardiovascular Disease Cancer
    Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .
    Digitoxin
  • HY-15176A
    Pyridostatin hydrochloride
    Maximum Cited Publications
    34 Publications Verification

    RR82 hydrochloride

    		 DNA/RNA Synthesis G-quadruplex Flavivirus Src Virus Protease Cancer
    Pyridostatin (RR82) hydrochloride is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin hydrochloride promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin hydrochloride targets the proto-oncogene Src. Pyridostatin hydrochloride reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells .
    Pyridostatin hydrochloride
  • HY-15176
    Pyridostatin

    RR82

    		 G-quadruplex Cancer
    Pyridostatin (RR82) is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin targets the proto-oncogene Src. Pyridostatin reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells .
    Pyridostatin
  • HY-19959
    Mirin
    5+ Cited Publications

    		 ATM/ATR Apoptosis Cancer
    Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC50=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .
    Mirin
  • HY-110111
    T2AA
    2 Publications Verification

    		 DNA/RNA Synthesis Cancer
    T2AA is a monoubiquitinated proliferating cell nuclear antigen (PCNA) inhibitor that prevents DNA repair, increases double-strand break (DSB) formation and promotes necroptosis and cell cycle arrest in G1 phase .
    T2AA
  • HY-10534
    Voreloxin
    3 Publications Verification

    SNS-595; Vosaroxin; AG 7352

    		 Topoisomerase Apoptosis Cancer
    Voreloxin (SNS-595; Vosaroxin; AG 7352) is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.
    Voreloxin
  • HY-19939S
    VX-984
    4 Publications Verification

    M9831

    		 DNA-PK Cancer
    VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .
    VX-984
  • HY-15176B
    Pyridostatin TFA
    Maximum Cited Publications
    34 Publications Verification

    RR82 TFA

    		 DNA/RNA Synthesis G-quadruplex Flavivirus Src Virus Protease Cancer
    Pyridostatin (RR82) TFA is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin TFA also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin TFA interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin TFA exhibits antiproliferative and antiviral activities. Pyridostatin TFA can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
    Pyridostatin TFA
  • HY-111183
    Neocarzinostatin (solution)
    1 Publications Verification

    Zinostatin; Vinostatin

    		 DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection Cancer
    Neocarzinostatin (solution), a potent DNA-damaging, anti-tumor antibiotic, recognizes double-stranded DNA bulge and induces DNA double strand breaks (DSBs). Neocarzinostatin induces apoptosis. Neocarzinostatin has potential for EpCAM-positive cancers treatment .
    Neocarzinostatin (solution)
  • HY-17469
    Gimeracil
    3 Publications Verification

    Gimestat

    		 DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD) Cancer
    Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil
  • HY-13703A
    Nimustine hydrochloride
    1 Publications Verification

    ACNU

    		 DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis p38 MAPK JNK AP-1 Cancer
    Nimustine hydrochloride (ACNU) is the hydrochloride salt form of Nimustine (HY-13703). Nimustine hydrochloride is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine hydrochloride activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
    Nimustine hydrochloride
  • HY-15176C
    Pyridostatin trihydrochloride
    Maximum Cited Publications
    34 Publications Verification

    RR82 trihydrochloride

    		 DNA/RNA Synthesis G-quadruplex Flavivirus Src Virus Protease Cancer
    Pyridostatin (RR82) trihydrochloride is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin trihydrochloride also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin trihydrochloride interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin trihydrochloride exhibits antiproliferative and antiviral activities. Pyridostatin trihydrochloride can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
    Pyridostatin trihydrochloride
  • HY-100705
    DMNB

    6-Nitroveratraldehyde

    		 Drug Intermediate Neurological Disease
    DMNB (6-Nitroveratraldehyde) is a photolabile proton donor that releases acidic substances when excited at a wavelength of 405 nM. DMNB can be used for the synthesis of no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA). DMNB is also applicable to the preparation of o-nitroaryl-bis (5-methylfur-2-yl) methanes and the synthesis of alpha-asarone (HY-N0700). DMNB is an enzyme involved in the non-homologous end joining (NHEJ) pathway responsible for DNA double-strand break (DSB) repair. DMNB can be used in PET studies of the dopaminergic system .
    DMNB
  • HY-121862
    CM03

    		DNA/RNA Synthesis Cancer
    CM03 is a potent DNA G-quadruplexes (G4s) ligand. CM03 can stabilise G4s, downregulating more G4-containing genes as well as increasing incidence of double-strand break events (DSBs) due to torsional strain on DNA and chromatin structure. CM03 has selective potency for pancreatic cancer cells .
    CM03
  • HY-16518
    Voreloxin Hydrochloride
    3 Publications Verification

    SNS-595 Hydrochloride; Vosaroxin Hydrochloride; AG 7352 Hydrochloride

    		 Topoisomerase Apoptosis Cancer
    Voreloxin Hydrochloride is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.
    Voreloxin Hydrochloride
  • HY-113064
    Selenocystine
    1 Publications Verification

    		 Endogenous Metabolite Cancer
    Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment .
    Selenocystine
  • HY-115531
    UNC-2170

    		DNA/RNA Synthesis Cancer
    UNC-2170 is a functionally active, fragment-like ligand for 53BP1 (IC50=29 µM; Kd=22 µM). UNC-2170 shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) .
    UNC-2170
  • HY-Q04764
    TI17

    		Thyroid Hormone Receptor Apoptosis Cancer
    TI17 is an inhibitor of the thyroid hormone receptor-interacting protein Trip13 and has anticancer activity. TI17 effectively inhibits multiple myeloma (MM) cell proliferation and induces cell cycle arrest and apoptosis. Trip13 is an AAA-ATPase that mediates double-strand break (DSB) repair; TI17 inhibits Trip13 function and increases DNA damage .
    TI17
  • HY-164279
    YTR107

    		DNA/RNA Synthesis Cancer
    YTR107 is a radiation sensitizer. YTR107 binds to nucleophosmin1 (NPM1) and inhibits pentamer formation. YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppresses repair of DNA double strand breaks, and enhances radiosensitization .
    YTR107
  • HY-W543137
    PT-ttpy

    		G-quadruplex DNA/RNA Synthesis Mitosis Cancer
    Pt-ttpy, a metallo-organic complex and potent G-quadruplex ligand, effectively triggers substantial telomere-related DNA damage in cancer cells by inhibiting telomerase and/or telomere functions, while also causing various chromatin abnormalities during mitosis, such as chromatin bridges, ultrafine bridges (UFBs), and double-stranded breaks (DSBs).
    PT-ttpy
  • HY-115552
    Simmiparib

    		PARP Cancer
    Simmiparib is a highly potent and orally active PARP1 and PARP2 inhibitor with IC50 values of 1.75 nM and 0.22 nM, respectively. Simmiparib has more potent PARP1/2 inhibition than its parent Olaparib (HY-10162). Simmiparib induces DNA double-strand breaks (DSB) accumulation and G2/M arrest in homologous recombination repair (HR)-deficient cells, thereby inducing apoptosis. Simmiparib exhibits remarkable anticancer activities in cells and nude mice bearing xenografts .
    Simmiparib
  • HY-176165
    CDK9/EZH2-IN-1

    		CDK Histone Methyltransferase Cancer
    CDK9/EZH2-IN-1 (Compound D16) is a CDK9/EZH2 dual-target inhibitor (IC50: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC50 values are 136.3, 171.3 and 315.7 nM, respectively) .
    CDK9/EZH2-IN-1
  • HY-100707
    IC 86621

    		DNA-PK Apoptosis Inflammation/Immunology Cancer
    IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC50 of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC50=68 µM). IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis .
    IC 86621
  • HY-149348
    DiPT-4

    		Topoisomerase PARP Apoptosis Cancer
    DiPT-4 is a dual TOP1/PARP1 inhibitor that induces massive DNA double-strand breaks (DSBs), cell cycle arrest, and apoptosis in cancer cells. DiPT-4 has the potential to overcome cancer drug resistance .
    DiPT-4
  • HY-146565
    DNA-PK-IN-8

    		DNA-PK Cancer
    DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin .
    DNA-PK-IN-8
  • HY-B1357R
    Digitoxin (Standard)

    		Reference Standards Bcl-2 Family Caspase Apoptosis HSV Na+/K+ ATPase Calcium Channel Cardiovascular Disease Cancer
    Digitoxin (Standard) is the analytical standard of Digitoxin. This product is intended for research and analytical applications. Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .
    Digitoxin (Standard)
  • HY-118897
    UNC-2170 maleate

    		DNA/RNA Synthesis Cancer
    UNC-2170 maleate is the maleate salt form of UNC-2170 (HY-115531). UNC-2170 maleate is a selective inhibitor for the methyl-lysine binding protein 53BP1, with IC50 of 29 µM and Kd of 22 µM. UNC-2170 maleate shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) .
    UNC-2170 maleate
  • HY-178021
    HDAC1-IN-11

    		HDAC DNA/RNA Synthesis Apoptosis RAD51 Caspase Cancer
    HDAC1-IN-11 (Compound 6) is a HDAC1 inhibitor with an IC50 of 106.6  nM. HDAC1-IN-11 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC1-IN-11 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC1-IN-11 can be used for chemotherapy of cancers like NSCLC research .
    HDAC1-IN-11
  • HY-178022
    HDAC6-IN-63

    		HDAC Apoptosis Caspase RAD51 DNA/RNA Synthesis Cancer
    HDAC6-IN-63 (Compound 7) is an orally active HDAC6 inhibitor with an IC50 of 145  nM. HDAC6-IN-63 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC6-IN-63 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC6-IN-63 can be used for chemotherapy of cancers like NSCLC research .
    HDAC6-IN-63
  • HY-123232
    KU-0058684

    		PARP Cancer
    KU-0058684 is a potent PARP inhibitor, with an IC50 of 3.2 nM for PARP-1. KU-0058684 significantly reduces DNA double strand break (DSB) repair .
    KU-0058684
  • HY-13703
    Nimustine

    		Apoptosis DNA Alkylator/Crosslinker DNA/RNA Synthesis p38 MAPK JNK AP-1 Cancer
    Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
    Nimustine
  • HY-178503
    dA-NHbenzylSCF 3

    		Apoptosis Cancer
    dA-NHbenzylSCF 3 is a radiosensitizer. dA-NHbenzylSCF 3 has low toxicity to cancer cells and normal cells, but can significantly enhance cancer cell death in the presence of ionizing radiation (IR). dA-NHbenzylSCF 3 promotes cell apoptosis by capturing electrons and inducing DNA double strand breaks (DSBs). dA-NHbenzylSCF 3 is often used in the research of cancer, such as prostate cancer and breast cancer .
    dA-NHbenzylSCF 3
  • HY-175466
    BER-IN-1

    		PARP DNA/RNA Synthesis Apoptosis Cancer
    BER-IN-1 is a base excision repair (BER) inhibtor, targeting DNA abasic sites. BER-IN-1 cleaves abasic sites via β- and β,δ-elimination mechanisms, disrupts the base excision repair (BER) pathway and leads to DNA double-strand breaks (DSBs). BER-IN-1 can enhance the effectiveness of the PARP inhibitor Olaparib (HY-10162) in homologous recombination (HR)-proficient cancer cells (MDA-MB-231, HeLa, and SKOV3). BER-IN-1 induces an S-phase arrest and apoptosis companied with Olaparib (HY-10162). BER-IN-1 can be used for the research of cancer, such as breast, cervical and ovarian cancer .
    BER-IN-1
  • HY-146316
    Topoisomerase II inhibitor 6

    		Topoisomerase Cancer
    Topoisomerase II inhibitor 6 (Compound 5), a tryptanthrin derivative, is a potent and selective inhibitor of topoisomerase II. Topoisomerase II inhibitor 6 exhibits antiproliferative activity on different tumor cell lines. Topoisomerase II inhibitor 6 blocks the cell cycle of CCRF-CEM in the G2 phase and induces DNA DSB. Topoisomerase II inhibitor 6 has the potential for the research of cancer diseases .
    Topoisomerase II inhibitor 6
  • HY-146566
    DNA-PK-IN-9

    		DNA-PK Cancer
    DNA-PK-IN-9 (compound YK6) is a potent DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 10.47 nM. DNA-PK-IN-9 can be used for researching anticancer .
    DNA-PK-IN-9
  • HY-134290
    8-Chloro-ATP

    		Topoisomerase Cancer
    8-Chloro-ATP, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP inhibits Topo II-catalyzed ATP hydrolysis .
    8-Chloro-ATP
  • HY-17469R
    Gimeracil (Standard)

    Gimestat (Standard)

    		 DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD) Reference Standards Cancer
    Gimeracil (Standard) is the analytical standard of Gimeracil. This product is intended for research and analytical applications. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil (Standard)
  • HY-134290A
    8-Chloro-ATP tetrasodium

    		Topoisomerase Cancer
    8-Chloro-ATP tetrasodium, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP tetrasodium inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP tetrasodium inhibits Topo II-catalyzed ATP hydrolysis .
    8-Chloro-ATP tetrasodium
  • HY-W777340
    Gimeracil-13C3

    Gimestat-13C3

    		 Isotope-Labeled Compounds DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD) Cancer
    Gimeracil- 13C3 (Gimestat- 13C3) is the 13C-labeled Gimeracil (HY-17469). Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil-13C3
  • HY-17469S
    Gimeracil-13C3,15N

    Gimestat-13C3,15N

    		 Isotope-Labeled Compounds Cancer
    Gimeracil- 13C3, 15N (Gimestat- 13C3, 15N) is 13C and 15N labeled Gimeracil. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil-13C3,15N
  • HY-150765
    PARP1-IN-12

    		PARP Apoptosis Cancer
    PARP1-IN-12 is a potent PARP1 inhibitor with an IC50 of 2.99 nM. PARP1-IN-12 exhibits antiproliferative activity, can induce cell apoptosis and cause cycle arrest at G2/M phase. PARP1-IN-12 also can induce DNA double strand breaks (DSBs) in BRCA-deficient cells .
    PARP1-IN-12
  • HY-168171
    ERK1/2 inhibitor 11

    		ERK Caspase Apoptosis Cancer
    ERK1/2 inhibitor 11 (compound L6) is a dual inhibitor of ERK1/2, lending to DSB accumulation and ERK1/2 expression degradation. ERK1/2 inhibitor 11 lowers the levels of BCL-2, and induces DNA damage by inhibiting PARP and ERK1/2. ERK1/2 inhibitor 11 activates caspase 3 to inducing apoptosis. .
    ERK1/2 inhibitor 11
  • HY-10534R
    Voreloxin (Standard)

    SNS-595 (Standard); Vosaroxin (Standard); AG 7352 (Standard)

    		 Reference Standards Topoisomerase Apoptosis Cancer
    Voreloxin (Standard) is the analytical standard of Voreloxin (HY-10534). This product is intended for research and analytical applications. Voreloxin (SNS-595; Vosaroxin; AG 7352) is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.
    Voreloxin (Standard)
  • HY-181254
    PARP1/NAMPT-IN-1

    		PARP NAMPT DNA/RNA Synthesis Apoptosis Cancer
    PARP1/NAMPT-IN-1 is a potent and dual PARP1 and NAMPT inhibitor with IC50 values of 1.2 nM and 6.7 nM, respectively. PARP1/NAMPT-IN-1 can disrupt the homologous recombination repair (HRR) pathway, leading to the accumulation of DNA double-strand breaks (DSBs), inducing cell cycle arrest and apoptosis, and also has antimigratory effects. PARP1/NAMPT-IN-1 exhibits excellent antitumor effects in a breast cancer xenograft model. PARP1/NAMPT-IN-1 can be used for the study of triple-negative breast cancer (TNBC) .
    PARP1/NAMPT-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: